About us

Brightstar Therapeutics is a biotechnology company focused on providing innovative treatment options that improve clinical outcomes and quality of life for people living with ocular surface diseases.

In 2023, Brightstar Therapeutics became the first company to offer a long-term solution for patients with impaired ocular healing through the BrightMEM corneal allograft, and we will continue to drive next-generation therapeutics for patients in need.

Our Pipeline

Brightstar Therapeutics is committed to advancing innovative, life-changing therapies.

Using our patented technology, we are developing a pipeline of cell therapy products.

Brightstar Therapeutics would like to acknowledge the support of the Aniridia Foundation International
of the study Treatment of Limbal Stem Cell Deficiency With Descemet's Membrane

Meet the Team

  • Rajan Shukla

    Chief Executive Officer

    READ BIO

  • Rusty Kelly

    Chief Operating Officer

    READ BIO

  • Jared Young

    Chief Commercial Officer

    Read Bio

  • Joseph Tauber, MD

    Chief Medical Officer

    READ BIO

  • Joshua Hou, MD

    Chief Scientific Officer

    READ BIO

Saving Sight CEO Tony Bavuso stated, “Brightstar Therapeutics has the potential to greatly advance corneal treatments and allow for more corneal tissue to be utilized, resulting in more people receiving the gift of sight.”